



ASX ANNOUNCEMENT

5 June 2025

PLACEMENT CLEANSING NOTICE

Further to ASX announcements on 30 May 2025 and 4 June 2025, Cardiex Limited (ASX: CDX) (the **Company**), advises that it has issued 42,500,000 fully paid ordinary shares (**Placement Shares**) to sophisticated and institutional investors at an issue price of \$0.04 per Placement Share (**Placement**). The Placement Shares were issued pursuant to the Company's placement capacity under ASX Listing Rule 7.1. A further 18,409,580 fully paid ordinary shares to be issued pursuant to tranche 2 of the Placement remain subject to shareholder approval and will be issued at a later date.

The Company gives notice under section 708A(5)(e) of the Corporations Act (**Corporations Act**) of the issue of the Placement Shares. The Corporations Act restricts the on-sale of securities issued without disclosure unless the sale is exempt under section 708 or 708A of the Corporations Act. By the Company giving this notice (**Notice**), a sale of the Placement Shares will fall within the exemption in section 708A(5) of the Corporations Act and they will be able to be traded immediately.

As required by section 708A(6) of the Corporations Act, in respect of the Placement the Company advises that:

1. the Placement Shares were issued without disclosure to investors under part 6D.2 of the Corporations Act on Thursday, 5 June 2025;
2. this Notice is given under section 708A(5)(e) of the Corporations Act;
3. as at the date of this Notice, the Company has complied with:
 - (a) the provisions of chapter 2M of the Corporations Act as they apply to the Company; and
 - (b) sections 674 and 674A of the Corporations Act; and
4. as at the date of this Notice, there is no excluded information of the type referred to in sections 708A(7) or 708A(8) of the Corporations Act, which is required to be disclosed by the Company.

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations
Rod Hinchcliffe
rod.hinchcliffe@mcpartners.com.au

Media Relations
Melissa Hamilton
melissa.hamilton@mcpartners.com.au

About Cardiex

Cardiex's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor® vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange ("ASX:CDX").